CONNECT WITH US:
linkedin [#161] Created with Sketch.
Explore our easy-to-use
Supplier Directory
Submitted by LCollins on
Ascension Cybersecurity Incident
Some non-emergent procedures are paused and several hospitals are on diversion as they navigate this cybersecurity incident.
May 10, 2024
Cyber security

St. Louis-based nonprofit and Catholic healthcare network Ascension, that operates 140 hospitals across more than a dozen states and Washington, DC, detected unusual activity in their network systems on May 8th and determined it was a cybersecurity incident. According to the news release, their team responded immediately, notified the appropriate authorities as well as business partners, and engaged Mandiant, a third-party expert, to assist in the investigation and remediation process.

“Safely caring for patients remains our highest priority as we navigate this cybersecurity incident,” per the release. “We are actively supporting our ministries as they continue to provide safe, patient care with established downtime protocols and procedures, in which our workforce is well trained. It is expected that we will be utilizing downtime procedures for some time. Patients should bring to their appointment notes on their symptoms and a list of current medications and prescription numbers or the prescription bottles so their care team can call in medication needs to pharmacies. We are working around the clock with internal and external advisors to investigate, contain, and restore our systems following a thorough validation and screening process. Our investigation and restoration work will take time to complete, and we do not have a timeline for completion.”

Systems that are currently unavailable include electronic health records system, MyChart (which enables patients to view their medical records and communicate with their providers), some phone systems, and various systems utilized to order certain tests, procedures and medications. The release stated that they have implemented established protocols and procedures to address these particular system disruptions in order to continue to provide safe care to patients.

Certain non-emergent elective procedures, tests and appointments have been temporarily paused. Due to downtime procedures, several hospitals are currently on diversion for emergency medical services in order to ensure emergency cases are triaged immediately.

Latest Industry news
View all Industry News
Bayer Logo
AskBio Earns FDA Rare Pediatric & Orphan Drug Status for AB-1003 in Limb-Girdle Muscular Dystrophy
Nov 07, 2024

Research Triangle Park, N.C.  – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

hotomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia (AML), a cancer of white blood cells.
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
Nov 01, 2024

The Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).

White oxy pills
Protega Pharmaceuticals Gains FDA Approval for Abuse-Deterrent ROXYBOND™ 10 mg Pain Tablet
Oct 29, 2024

PRINCETON, N.J - Protega Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ROXYBOND™ (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ROXYBOND is the first and only FDA-approved abuse-deterrent IR 10 mg oxycodone formulation that is expected to reduce abuse by intranasal and intravenous routes.